TNFRSF18 and neoplasm: They performed single-cell RNA sequencing of over 2000 tumor-infiltrating CD8+ T cells in mice subjected to PD-1 and GITR antibody combination therapy and concluded, that the effector function of expanded CD8+ T cells is synergistically enhanced by maintaining the balance between the key homeostatic regulators CD226 and the T cell immune receptor containing Ig and ITIM domains (TIGIT), which consequently contributes to a strong survival performance.